BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/bioray-announces-first-patient-in-for-phase-i-clinical-study-of-bry812-a-novel-liv-1-targeting-antibody-drug-conjugate-301979526.html
en | boerse | 67934256 |
